ArticleJournal of medical case reports2026
Coronavirus disease 2019-associated mucormycosis and cytomegalovirus infection: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucormycosis is a severe opportunistic fungal infection that has become a notable complication in patients recovering from coronavirus disease 2019, particularly in individuals with preexisting diabetes mellitus or a history of corticosteroid administration. Coinfection with cytomegalovirus in immunocompromised patients with coronavirus disease 2019 is increasingly documented yet remains insufficiently acknowledged. This case is significant owing to the uncommon simultaneous occurrence of cutaneous mucormycosis and cytomegalovirus infection in a post-coronavirus disease patient, underscoring the diagnostic and therapeutic challenges associated with these dual infections. CASE PRESENTATION: The purpose of this report is to discuss a 56-year-old man of South Asian/Pakistani descent with a history of diabetes mellitus and hypertension. He was diagnosed with post-coronavirus disease pneumonia with an anterior abdominal wall lesion that did not resolve after treatment for cutaneous mucormycosis, which was diagnosed on histopathology. Liposomal amphotericin B was administered intravenously, and the patient underwent surgical wound debridement. However, the patient was readmitted owing to sepsis and had a cytomegalovirus reactivation confirmed by polymerase chain reaction testing. Ganciclovir was given intravenously. The patient's health continued to deteriorate until he died from complications of his disease in spite of receiving aggressive medical and surgical treatment.
conclusionThis case illustrates the need for prompt recognition and treatment of concurrent opportunistic infections in patients who are immunocompromised owing to coronavirus disease 2019. A multidisciplinary proactive approach will be necessary to improve survival and patient outcomes in similarly complex patient cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.